Targeting Hedgehog signaling to improve treatment for ovarian cancer
Hedgehog/Gli1-targeted therapies to overcome ovarian cancer chemoresistance and disease recurrence
['FUNDING_R01'] · TEXAS TECH UNIVERSITY HEALTH SCIS CENTER · NIH-10545765
This study is looking at how a specific pathway in ovarian cancer cells can be targeted to help make treatments work better for patients whose cancer keeps coming back after initial therapies.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | TEXAS TECH UNIVERSITY HEALTH SCIS CENTER (nih funded) |
| Locations | 1 site (LUBBOCK, UNITED STATES) |
| Trial ID | NIH-10545765 on ClinicalTrials.gov |
What this research studies
This research investigates how targeting the Hedgehog signaling pathway can help overcome the challenges of chemoresistance and recurrence in ovarian cancer. The study focuses on understanding the molecular mechanisms that allow ovarian cancer cells to survive and resist treatment, particularly after initial therapies have failed. By inhibiting specific proteins involved in this pathway, the researchers aim to enhance the effectiveness of existing treatments and potentially develop new therapeutic strategies. Patients may benefit from insights that could lead to more effective treatment options for recurrent ovarian cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with ovarian cancer who have experienced recurrence after initial treatment.
Not a fit: Patients with early-stage ovarian cancer who have not yet undergone treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with recurrent ovarian cancer, potentially increasing survival rates.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in other cancers, suggesting potential for success in this approach for ovarian cancer.
Where this research is happening
LUBBOCK, UNITED STATES
- TEXAS TECH UNIVERSITY HEALTH SCIS CENTER — LUBBOCK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PALLE, KOMARAIAH — TEXAS TECH UNIVERSITY HEALTH SCIS CENTER
- Study coordinator: PALLE, KOMARAIAH
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.